---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-012679"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T18:49:45.058248+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q1 2023 net loss $4.04M ($0.15/share); cash $23.85M; clinical progress on CM04S1 and Gedeptin

## Summary
- Net loss $4,037,916 ($0.15/share) vs $2,427,515 ($0.34/share) in Q1 2022; R&D expense $2.82M (+112% YoY); G&A $1.45M (+23%).
- Cash $23.85M at March 31, 2023, down $3.76M from Dec 31, 2022; no revenue reported.
- Phase 2 CM04S1 COVID-19 vaccine trial data presented at World Vaccine Congress shows immunogenicity in immunocompromised patients.
- Gedeptin Phase 1/2 cancer trial expanded to three NCI-designated centers; enrollment expected to complete in Q2 2023.
- Expanded NIH license rights to include orthopoxviruses (Mpox, smallpox) for MVA-based vaccine development.

## SEC filing metadata
- accession: 0001437749-23-012679
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774923012679/0001437749-23-012679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774923012679/govx20230503_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-012679
- JSON: https://secwatch.observer/filing/0001437749-23-012679.json
- Plain text: https://secwatch.observer/filing/0001437749-23-012679.txt

## Key facts
- Earnings Releases
  GeoVax Labs, Inc. reported three months ended March 31, 2023 results: net income $4,037,916, EPS $0.15 per share.
  - Period: three months ended March 31, 2023
  - Net income: $4,037,916
  - EPS: $0.15 per share
  - Result: reported results
  source text: Net Loss : Net loss for the three months ended March 31, 2023, was $4,037,916, or $0.15 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774923012679/0001437749-23-012679-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.